A policy review follows months of turmoil at the cancer center, which pledged an overhaul, including new rules on public disclosure and limits on outside profits.
The cancer center will now bar top officials from sitting on outside boards of for-profit companies, and is conducting a wide-scale review of other policies.
AstraZeneca has hired Dr. José Baselga, the former chief medical officer at Memorial Sloan Kettering, to lead its cancer research unit.
One of the nation’s top cancer hospitals has grappled with how to bring breakthrough treatments to market while remaining true to its mission.
Dr. José Baselga, the former chief medical officer of Memorial Sloan Kettering Cancer Center, was asked to resign after he failed to disclose corporate ties in dozens of scientific articles.
Prominent Doctors Aren’t Disclosing Their Industry Ties in Medical Journal Studies. And Journals Are Doing Little to Enforce Their Rules
The dean of Yale’s medical school, the incoming president of a prominent cancer group and the head of a Texas cancer center are among leading medical figures who have not accurately disclosed their relationships with drug companies.
The hospital’s chief medical officer resigned last month after failing to disclose company ties in medical journals. Now, Memorial Sloan Kettering researchers, including chief executive Dr. Craig B. Thompson, are updating their own conflict-of-interest disclosures.
Under scrutiny for the hospital’s industry ties and compensation, Dr. Craig B. Thompson stepped down from two company boards.
The executive told Memorial Sloan Kettering staff that the hospital did not do enough to limit the industry conflicts of its chief medical officer, who has resigned.
A vice president at Memorial Sloan Kettering received a stake of nearly $1.4 million in a biotech company for representing the hospital on its board. He will give back his stake as the cancer center grapples with questions about conflicts of interest.
The change highlights the challenges facing Memorial Sloan Kettering, one of the nation’s most prestigious cancer centers, amid a widening crisis.
A for-profit venture with exclusive rights to use the cancer center’s vast archive of tissue slides has generated concerns among pathologists at the hospital, as well as experts in nonprofit law and corporate governance.
Dr. José Baselga, the hospital’s chief medical officer, stepped down days after a report by ProPublica and the New York Times that he failed to disclose millions of dollars in payments from the health care and drug industry in research articles.
The move comes after ProPublica and The New York Times reported that one of its top executives failed to report payments from drug and health care companies in dozens of medical journal articles.
A senior official at Memorial Sloan Kettering Cancer Center has received millions of dollars in payments from companies that are involved in medical research. His omissions expose how weakly conflict-of-interest rules are enforced by journals.
ProPublica and The New York Times have partnered to tell the stories of Americans living daily with the reality of high-cost drugs. There are millions of others just like them.
As insurers ask consumers to pay a greater share of their drug costs, it may be cheaper to pay cash than use your insurance card. One expert estimates that consumers could be overpaying for as many as 1 in 10 prescriptions.
Online prescription sites may help you find cheaper prices for some drugs, sometimes without using your insurance.
Drug companies and doctors have been accused of fueling the opioid crisis, but some question whether insurers have played a role, too.
The New York Times and ProPublica have teamed up to investigate who is to blame for skyrocketing drug prices — and have turned up some surprising answers.